You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

melphalan

Showing 26 - 50 of 510
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Recruiting
  • Plasma Cell Myeloma
  • Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 27, 2022

Multiple Myeloma Trial in Berne (Melphalan, Bendamustine)

Completed
  • Multiple Myeloma
  • Berne, Switzerland
    Department for Medical Oncology University Hospital/Inselspital
Jul 29, 2021

Hematologic Malignancies Trial in New York (Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan)

Recruiting
  • Hematologic Malignancies
  • Busulfan 3.2 mg/kg/day
  • +5 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 14, 2022

Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma Trial in Houston (procedure, drug, other)

Active, not recruiting
  • Plasma Cell Leukemia
  • +3 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 6, 2022

Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell

Completed
  • Hematologic Malignancies
  • +7 more
  • Melphalan
  • San Francisco, California
    University of California, San Francisco
Sep 27, 2021

Multiple Myeloma Trial in Torino (Velcade, Melphalan, Prednisone)

Recruiting
  • Multiple Myeloma
  • Torino, TO, Italy
    Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
May 25, 2022

Multiple Myeloma Trial in Canada (Busulfan, Melphalan, Lenalidomide)

Completed
  • Multiple Myeloma
  • Edmonton, Alberta, Canada
  • +9 more
Sep 20, 2022

Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult

Active, not recruiting
  • Adult Acute Lymphoblastic Leukemia in Remission
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Trial in Duarte (drug, other,

Recruiting
  • Acute Lymphoblastic Leukemia
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022

Testicular Cancer Trial in Houston, Seattle (Gemcitabine, Docetaxel, Melphalan)

Active, not recruiting
  • Testicular Cancer
  • Houston, Texas
  • +1 more
Dec 5, 2022

Hematopoietic Stem Cell Transplantation Trial in Seoul (Melphalan)

Recruiting
  • Hematopoietic Stem Cell Transplantation
  • Melphalan
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Jun 23, 2021

Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)

Active, not recruiting
  • Sickle Cell Disease
  • Hackensack, New Jersey
    Hackensack University Medical Center
Feb 4, 2022

Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,

Active, not recruiting
  • Autologous Hematopoietic Stem Cell Transplant Recipient
  • +4 more
  • Duarte, California
    City of Hope
Mar 17, 2022

Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma Trial in Minneapolis, Portland (Carboplatin, Etoposide,

Completed
  • Anaplastic Oligoastrocytoma
  • +3 more
  • Minneapolis, Minnesota
  • +1 more
Mar 11, 2022

Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid

Recruiting
  • Previously Treated Myelodysplastic Syndrome
  • +3 more
  • Fludarabine Phosphate
  • +9 more
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Jan 7, 2022

GVHD, Leukemia, Lymphoma Trial in Duarte (biological, drug, procedure, radiation, other)

Active, not recruiting
  • Graft Versus Host Disease
  • +2 more
  • rituximab
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome Trial in Duarte (Fludarabine, Itacitinib Adipate,

Active, not recruiting
  • Acute Leukemia
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Multiple Myeloma Trial in Saint Petersburg (Melphalan, Nivolumab, Autologous Stem Cell Transplantation)

Recruiting
  • Multiple Myeloma
  • Melphalan
  • +2 more
  • Saint Petersburg, Russian Federation
    Boris V Afanasyev, MD, Prof.
Apr 4, 2022

Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma Trial (Autologous Tumor Infiltrating Lymphocytes, Melphalan,

Not yet recruiting
  • Metastatic Uveal Melanoma
  • Metastatic Cutaneous Melanoma
  • Autologous Tumor Infiltrating Lymphocytes
  • +2 more
  • (no location specified)
Oct 14, 2022

Multiple Myeloma Trial in New York (Tremelimumab, Durvalumab, Prevnar-13)

Terminated
Has Results
  • Multiple Myeloma
  • New York, New York
  • +1 more
Oct 3, 2022

Neuroblastoma Trial in Minneapolis (Thiotepa, Cyclophosphamide, Melphalan)

Recruiting
  • Neuroblastoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Retinoblastoma, Chemo Effect Trial in Guangzhou (Topotecan, Melphalan)

Recruiting
  • Retinoblastoma
  • Chemotherapy Effect
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Mar 12, 2021

Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)

Recruiting
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Jan 25, 2023

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022